US LNG exports surge but will buyers in China turn up?
HONG KONG, SHANGHAI & FLORHAM PARK, NJ – HUTCHMED (China) Limited has presented new data at the European Lung Cancer Congress 2025, demonstrating the effectiveness of savolitinib in combination with TAGRISSO® for treating MET-high lung cancer. The Phase II SAVANNAH trial revealed significant response rates in patients with EGFR mutated non-small cell lung cancer who had previously progressed on TAGRISSO® treatment.
The study reported an objective response rate of 56% with a median duration of response ranging from 7.1 to 9.9 months and median progression-free survival of 7.4 to 7.5 months. These outcomes were consistent across investigator and blinded independent central review assessments. Additionally, the safety profile of the combination therapy aligned with the known effects of each drug, with no new safety concerns emerging.
Savolitinib, a MET tyrosine kinase inhibitor, is being developed by AstraZeneca (NASDAQ:AZN) and HUTCHMED. It has already received Fast Track Designation from the FDA for this treatment setting in 2023. The SAVANNAH trial, which enrolled over 360 patients globally, is part of a broader effort to address the challenge of resistance in advanced lung cancer treatment.
In another Phase IIIb study in China, savolitinib showed a long-term survival benefit for patients with MET exon 14 skipping alteration NSCLC. Results indicated a median overall survival of 28.3 months in treatment-naïve patients and 25.3 months in previously treated patients. The drug is approved in China and marketed as ORPATHYS® for this patient group.
The press release also mentioned surufatinib, another HUTCHMED product, which in combination with PD-1/PD-L1 antibodies, may offer a survival benefit as maintenance therapy for extensive-stage small cell lung cancer following first-line chemo-immunotherapy.
HUTCHMED is a biopharmaceutical company focused on developing targeted therapies for cancer and immunological diseases. The company emphasizes the discovery and global development of new treatments, with several medicines already marketed in China and one approved internationally.
The information presented is based on a press release statement and reflects the company’s current expectations about the potential therapeutic benefits of savolitinib and surufatinib in lung cancer treatment. These statements are forward-looking and subject to risks and uncertainties that could affect the actual outcomes of ongoing clinical studies and regulatory approvals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.